Cyxone’s chairman of the board Bert Junno expands his holding in the company and exercises warrants

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company’s chairman of the board Bert Junno increases his holding in Cyxone by exercise of 100 000 warrants.

Bert Junno, chairman of the board for Cyxone, commented: “Cyxone is currently in a very eventful phase with several milestones on the horizon. The success that the candidates, T20K and Rabeximod, have been able to show so far has made me more convinced of the potential of Cyxone. I see a very bright future for the company, which is why I now choose to expand my private holdings.”

Chairman of the board Bert Junno has increased his private holding with subscription of 100.000 shares through the exercise of equal number of warrants of series 03.

Contact
Cyxone AB (publ)

Kjell G. Stenberg, CEO
Phone: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21

211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se. www.cyxone.com

Tags:

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.www.cyxone.com

Subscribe